Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis

  • Menter A
  • Thaçi D
  • Papp K
  • et al.
N/ACitations
Citations of this article
34Readers
Mendeley users who have this article in their library.

Abstract

Copyright © 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved. BACKGROUND: ESPRIT is an ongoing, 10-year, observational registry, evaluating long-term safety and effectiveness of adalimumab treatment in routine clinical practice for patients with moderate to severe, chronic plaque psoriasis. OBJECTIVES: Initial 5-year results are reported. METHODS: Two populations were analyzed: the "all-treated" population received 1 or more adalimumab doses in registry, continuing adalimumab treatment from a current prescription or previous study participation, and included the "new-prescription" population initiating adalimumab 4 weeks or earlier preregistry entry. RESULTS: Data were collected from September 26, 2008, through November 30, 2013, for all-treated (n = 6059), which included new-prescription (n = 2580, 42.6%); median registry exposure was 765 and 677 days, respectively. In all-treated, rate (events per 100 patient-years of total adalimumab exposure [E/100PY]) of serious treatment-emergent adverse events (inside or outside of the registry) was 4.3 E/100PY, serious infection 1.0 E/100PY, malignancies 0.9 E/100PY (nonmelanoma skin cancers 0.6 E/100PY; melanomas < 0.1 E/100PY). Standardized mortality ratio was 0.30 (95% confidence interval 0.19-0.44). Physician Global Assessment clear or minimal (effectiveness parameter) was achieved by 57.0% at 12 months and 64.7% at 60 months of treatment. LIMITATIONS: Observational data are subject to outcome-reporting bias. CONCLUSION: No new safety signals were observed with adalimumab treatment during this initial 5-year registry review. Observed number of deaths was below expected. As-observed effectiveness remained stable through 60 months.

Cite

CITATION STYLE

APA

Menter, A., Thaçi, D., Papp, K. A., Wu, J. J., Bereswill, M., Teixeira, H. D., … Williams, D. A. (2015). Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. Journal of the American Academy of Dermatology, 73(3), 410-419.e6. https://doi.org/10.1016/j.jaad.2015.06.038

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free